Using CDX models, we present evidence that the combination of PRMT5 inhibitors with either DDR or cell cycle inhibitors significantly increased the anti-lymphoma potency in MCL with ATM and/or TP53 lesions, attributing to the intrinsic interaction between PRMT5 and DDR pathways. This evidence concerns the gene PRMT5 and lymphoma.